Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 26, 2024
Discovery & Translation
Letter from the Editor: the tea leaves of innovation brewing in academia
Trends from BioCentury’s Distillery yield clues about clusters of breakthroughs and hot topics to watch
BioCentury | Mar 6, 2024
Discovery & Translation
Distillery spotlight: new Type II diabetes mechanisms from academia
New targets to drive insulin secretion, islet cell numbers and receptor localization from BioCentury’s survey of the 2023 translational literature
BioCentury | Oct 12, 2023
Distillery Therapeutics
UNC119B-binding small molecule for insulin sensitization in diabetes
BioCentury | Jun 27, 2019
Distillery Therapeutics
An insulin-conjugated dual SLC2A1/SLC2A4 inhibitor for diabetes
BioCentury | Aug 10, 2018
Targets & Mechanisms
Getting to function
How a new sarcopenia target could directly address muscle function deficits
BioCentury | Oct 6, 2016
Product R&D
Encoding glucose control
How Renova is using gene therapy for diabetes
Items per page:
1 - 10 of 16